Skip to content Menu
Science Chronicle

Science Chronicle

A Science and Technology Blog

Sidebar
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad

Category: TB Alliance

Posted on August 19, 2019

Pretomanid: XDR-TB may soon become easily treatable

Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…

Continue Reading
Posted on August 16, 2019August 18, 2019

Explainer: What makes the new drug-resistant TB medicine Pretomanid promising

When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the…

Continue Reading
Posted on January 19, 2016March 21, 2016

‘Child-friendly paediatric TB drugs will be a game changer’

Treating young children afflicted with drug-sensitive TB disease will no longer be the same. After years of neglect, the availability of flavoured, easily dissolvable first-line TB drugs in correct doses…

Continue Reading
Posted on January 19, 2016March 21, 2016

Child-friendly TB drugs launched

For the first time, child-friendly TB drugs for first-line medication in a fixed-dose combination was launched by TB Alliance, UNITAID and WHO at the 46th Union World Conference on Lung…

Continue Reading
Posted on January 16, 2016June 28, 2016

PaMZ drug combination is a game changer for TB and MDR-TB treatment

A novel drug combination (PaMZ) designed to treat both drug-sensitive and MDR-TB, including those who are HIV positive, is advancing to the crucial Phase III human clinical trial. If all…

Continue Reading
Posted on January 14, 2016July 6, 2016

Child-friendly, first-line TB combination drugs will be available in 2016: Dr. Mel Spigelman

Dr. Mel Spigelman, President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance) is regarded as one of the world’s leading experts in tuberculosis and…

Continue Reading
Follow Science Chronicle on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 10,662 other followers

Archives

Social

  • View Prasad.Ravindranath’s profile on Facebook
  • View @RPrasad12’s profile on Twitter
  • View Prasad.Ravindranath@gmail.com’s profile on Google+

Recent Posts

  • Is India witnessing the beginning of a second wave? February 27, 2021
  • Vaccinate all above 45 years to avoid vaccine inequities February 26, 2021
  • People above 45 years with comorbidities will need doctor certificate, says task force member February 25, 2021
  • Are the variants causing a spike in cases in India? February 24, 2021
  • Covaxin has only 10% takers nationally; less than 1% uptake in 12 States, Union Territories February 22, 2021

Most Read Posts

  • Is India witnessing the beginning of a second wave?
  • 'Serum’s pneumococcal vaccine will be available by June 2020'
  • Easy way to tell if the foil used in Thanjavur painting is gold or fake
  • No correlation between Ct values of PCR test and COVID-19 severity
  • India's TB control programme renamed to reflect its intent on ending TB
  • Social factors too determine skin colour of Indians
  • Are the variants causing a spike in cases in India?
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
Create a website or blog at WordPress.com
Top
Follow Science Chronicle on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 10,662 other followers

Archives

Cancel

 
Loading Comments...
Comment
    ×